nirogacestat,bortezomib,daratumumab,pomalidomide,teclistamab,lenalidomide
springworks therapeutics,janssen,takeda,genmab,bms
['lenalidomide', 'majestec,(-majestec-1),(-majestec1),(-majestec 1),(-majestec-3),(-majestec3),(-majestec 3),(-majestec-i),(-majestec i),(-majesteci)', 'teclistamab', 'daratumumab', 'mmsm', 'multiple myeloma', 'majestec-2', ' lena']
encouraging early clinical activity was demonstrated with the combination of teclistamab plus daratumumab, lenalidomide, in patients with relapsed or refractory multiple myeloma, according to the phase 1b majestec-2 trial. #ash22 #mmsm 
Oncology news and insights from leading researchers and cancer centers.